Industry data and trends for New Approach Methodologies. Track market growth, investment activity, and regulatory developments.
FDA Modernization Act 2.0 (2022) removed animal testing mandates. First ISTAND-qualified OoC platform approved in 2024. EMA following with parallel initiatives.
NAMs companies raised $500M+ in 2023-2024. Major pharma partnerships increasing. Large pharma building in-house capabilities.
Integration of AI/ML with wet lab NAMs. Digital twins enhancing predictions. Multi-organ systems reaching commercial readiness.
Top 20 pharma companies have NAMs programs. CROs expanding NAMs services. Academic adoption accelerating.
Market data presented is compiled from publicly available industry reports and estimates. Figures are approximate and intended for educational purposes. Actual market conditions may vary. This information should not be used as the sole basis for investment decisions.
© 2025 Patient Analog. All rights reserved.
Educational Resource for NAMs Technologies
© 2025 Patient Analog. All rights reserved.
Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.
Free to share for educational purposes with attribution.